Loading patent…
AssigneeRiken
InventorsMasaru Taniguchi, Haruhiko Koseki, Hiroshi Watarai, Shin-ichiro Fujii
Estimating the term…
The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.
-14. (canceled)
A method for immunocyte therapy comprising administering an effective amount of NKT cells to a subject, wherein the NKT cells have been obtained by differentiating in vitro cells having the α-chain region of a T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific manner, wherein the administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of NKT cells.
The method according to claim 22, wherein the NKT cell is a human NKT cell.
A bank of human NKT cell-derived cells wherein the α-chain region of the T cell receptor gene have been rearranged to uniform Vα-Jα in an NKT cell receptor-specific manner, or NKT cells obtained by differentiating said cells in vitro.
Dependencies are inferred from the claim text.